LUNA LABS USA LLC — Department of Defense STTR Phase II: DHA H2-0804, TITLED "SHELF-STABLE ANTIBIOTIC HYBRID EXOSOMES FOR THE TOPICAL TREATMENT OF
LUNA LABS USA LLC — STTR Phase II award from Department of Defense.
Phase II STTR prototype / development signal
- Phase II is where Department of Defense funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- Obligated amount $1,299,999 is consistent with substantial Phase II-scale effort; compare to related awards from the same agency.
- Tagged technology areas: Human Performance & Medical. Follow those hubs for open topics and peer winners in the same cluster.
Summary
Luna Labs USA LLC won a $1.3 million STTR Phase II contract from the Defense Health Agency to develop shelf-stable antibiotic hybrid exosomes for topical treatment of wound infections. The goal is a practical, refrigeration-free medical product that can effectively fight infections in wounds.
- Amount
- $1,299,999
- Agency
- Department of Defense · Defense Health Agency
- Program / Phase
- STTR · Phase II
- NAICS
- 541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- Place of performance
- VA
- Period
- 2025-02-05 → 2027-06-04
Technology domains
Description
DHA STTR PHASE II PROPOSAL H2-0804, TITLED "SHELF-STABLE ANTIBIOTIC HYBRID EXOSOMES FOR THE TOPICAL TREATMENT OF WOUND INFECTIONS", MEDICAL R&D CONTRACT.